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Abstract: Down syndrome (DS) is the most common genetic cause of intellectual disability that is
associated with an increased risk to develop early-onset Alzheimer-like dementia (AD). The brain
neuropathological features include alteration of redox homeostasis, mitochondrial deficits,
inflammation, accumulation of both amyloid beta-peptide oligomers and senile plaques, as well as
aggregated hyperphosphorylated tau protein-containing neurofibrillary tangles, among others. It is
worth mentioning that some of the triplicated genes encoded are likely to cause increased oxidative
stress (OS) conditions that are also associated with reduced cellular responses. Published studies
from our laboratories propose that increased oxidative damage occurs early in life in DS population
and contributes to age-dependent neurodegeneration. This is the result of damaged, oxidized
proteins that belong to degradative systems, antioxidant defense system, neuronal trafficking. and
energy metabolism. This review focuses on a key element that regulates redox homeostasis, the
transcription factor Nrf2, which is negatively regulated by BACH1, encoded on chromosome 21.
The role of the Nrf2/BACH1 axis in DS is under investigation, and the effects of triplicated BACH1
on the transcriptional regulation of Nrf2 are still unknown. In this review, we discuss the
physiological relevance of BACH1/Nrf2 signaling in the brain and how the dysfunction of this
system affects the redox homeostasis in DS neurons and how this axis may contribute to the
transition of DS into DS with AD neuropathology and dementia. Further, some of the evidence
collected in AD regarding the potential contribution of BACH1 to neurodegeneration in DS are also
discussed.
Keywords: oxidative stress; BACH1; Nrf2; Down syndrome; Alzheimer disease

1. Genetics of Oxidative Stress in Down Syndrome
Down syndrome (DS) or trisomy 21 is one of the most common genetic disorder displaying
phenotypic features that include neurodevelopmental defects, neuronal dysfunction, and accelerated
aging, among others Cenini, Dowling [1], [2,3]. Further, DS individuals are at increased risk to
develop a type of dementia that mimics the clinical and pathological features course of Alzheimer
disease (AD), with the deposition of amyloid plaques and neurofibrillary tangles. Interestingly, DS is
emerging as a disorder etiologically related to oxidative stress (OS) mainly due to triplication of Cu,
Zn-superoxide dismutase (SOD-1), encoded on chromosome 21 (Hsa21). However, recent reports
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showed that OS is driven not only from overexpression of some Hsa21 genes, but also from a
dysregulation of gene/protein expression associated with the trisomy [4].
OS results from either elevated production of reactive oxygen and nitrogen species (ROS/RNS)
or by reduced antioxidant responses. The central nervous system (CNS) contains high levels of fatty
acids that in the presence of high metabolic flux are a fertile ground for lipid peroxidation reactions
responsible of generating increasing amount of free radicals as well as highly reactive products, such
as 4-hydroxynonenal (HNE) [5–8]. In addition, superoxide anion (O2−•), hydrogen peroxide (H2O2),
and hydroxyl radical (HO•), are continuously produced as by-products of aerobic respiration and
various other catabolic/anabolic processes [9]. As a result, neuronal cells are highly susceptible to
redox imbalance and to accumulate oxidative damage [10].
As an essential link to OS, mitochondrial dysfunction occurs whenever redox imbalances
overcome the intracellular defense system, due to the main role of mitochondrial activity in oxygen
metabolism and ROS production [11]. By-products of normal mitochondrial metabolism and
homeostasis include the build-up of potentially damaging levels of ROS. A major source of free
radicals is the mitochondrial oxidative phosphorylation pathway (OXOPHOS), in which electron
leakage causes the formation of O2−• that, in turn, is converted by mitochondrial resident manganese
superoxide dismutase (MnSOD) into H2O2 and O2 [12,13]. In line with this evidence, dysfunction of
complex I has been found to be involved in the overproduction of ROS in skin fibroblast from DS,
isolated from both fetal and adult subjects [14].
Accumulating studies implicate OS in DS pathological phenotypes [15–17], though the exact
mechanisms through which oxidative damage translate into clinical features of DS need to be
clarified. It is likely that OS is a chronic condition in DS brain, that initiates already during embryonic
development and further accumulates with aging, representing a strong risk factor for subsequent
neurodegeneration [18,19].
In order to better understand and appreciate the causes of OS in DS brain, initial explanations
can be obtained by mapping the Hsa21 on which a number of genes (Table 1) such as SOD1, amyloid
precursor protein (APP), the transcription factor BTB and CNC homology 1 (BACH1), the Protein Cets-2 (ETS2), carbonyl reductase (CBR), S100 calcium-binding protein B (S100B), among others, are
directly involved in the overproduction of ROS as found in DS individuals and in mouse models
thereof [20].
Table 1. List of some genes located on Hsa21 linked to OS, as discussed in the text.
Gene on
Hsa21
SOD-1
(Cu,Znsuperoxide
dismutase 1)

Molecular
Function

Biological Process

Relevance in Down Syndrome
Triplication of SOD-1 in DS brain results in an imbalance
in the ratio of SOD-1 to CAT and GPX (two enzymes
involved in its metabolism), thus leading to the
accumulation of H2O2 in the cells.

Oxidoreductase

Antioxidant
Response

APP (amyloid
precursor
protein)

Heparin-binding,
Protease inhibitor

Apoptosis, Cell
adhesion,
Endocytosis, Notch
signaling pathway
and Aβ processing

BACH1 (BTB
Domain and
CNC Homolog
1)

DNA-binding,
Transcription
regulation

Antioxidant
Response

Triplication of BACH1, as a negative transcription
regulator, in DS brain could block the induction of
antioxidant genes, therefore promoting increased OS in
the cell.

Oxidative stress
Response

Triplication of CBR in DS play a role in exacerbating OS.
Carbonyls are toxic metabolic intermediates that are
mainly detoxified by aldehyde dehydrogenase or reduced
by CBR and/or alcohol dehydrogenase to their
corresponding alcohols. Increased levels of these enzymes
were detected in the brain of DS patients, likely in
response to elevated carbonyls production in DS.

CBR
(Carbonyl
reductase)

Oxidoreductase

Triplication of APP causes the over-production of Aβ (140/42) in DS brain. Deposition of senile plaques of Aβ is
observed in post-mortem brain and plasma from DS
compared with non-DS individuals.
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Transcription
regulation

Cell differentiation,
maturation and
signaling

Ca2+-binding
protein

Neurotrophic factor

Triplication of Ets-2 could play a role in the increased
susceptibility of DS cells to undergo apoptosis given
common pathophysiological features shared between Ets2 overexpressing transgenic mice and individuals with
DS.
Triplication of S100β in DS corresponds to an increase of
its expression levels in astrocytes in association with
neuritic plaques. In addition, chronic overexpression of
S100β contributes to increased neuronal and neuritic
βAPP expression with consequent accelerated amyloid
deposition, as well as abnormal growth of neurites in βamyloid plaques, similar to observations in middle-aged
DS patients.

Among trisomic genes, SOD1 is one of the first lines of antioxidant defense by catalyzing the
conversion of O2•− to molecular oxygen (O2) and H2O2, which can be neutralized by catalase (CAT)
and by glutathione peroxidase (GPX) to water [21]. Moreover, the triplication of Hsa21 is not
accompanied by a parallel increase of CAT and GPX, resulting in imbalance in SOD1/CAT levels and
those of SOD1/GPX, with an accumulation of H2O2 [22]. Interestingly, in all DS tissues an altered
SOD-1/GPX activity ratio has been observed [5], that may partially explain higher levels of H2O2 and
its by-products. In addition to CAT and GPX, a decreased expression of peroxiredoxin 2 also was
detected in DS fetal brain, which further contribute to the increased susceptibility of DS neurons to
undergo oxidative damage [23].
Intriguingly, aberrant expression of SOD seems to be associated with mitochondrial impairment.
Indeed, transgenic mice overexpressing wild-type human SOD1 (Tg-SOD1) show many
mitochondrial defects such as increased mitochondrial swelling and vacuolization, that also are
associated with learning and memory disturbance [7]. In addition, Tg-SOD1 mice have altered levels
of ATP synthase alpha/beta chain and elongation factor Tu, while no changes in the levels of
antioxidant proteins were observed [7]. Taken together, these alterations correlate with synaptosomal
damage and neuronal loss in the brain of Tg-SOD1, ultimately leading to cognitive deficits in DS.
Several studies reported that defects of mitochondrial structure and function are associated with
increased ROS production [24–27]. In line with this assumption, mitochondrial dysfunction is
considered a pathological signature of DS, also in the presence of increased OS condition [25].
Neurons of DS patients exhibited a significant increase in intracellular ROS levels together with
elevated lipid peroxidation [5,26,27]. The DS mitochondrial phenotype includes: (i) reduced ability
to produce ATP through OXPHOS; (ii) decreased respiratory capacity; and (iii) disruption of
mitochondrial membrane potential, all events associated with loss of mitochondrial dynamics. These
mitochondrial defects are present in all DS cell types, from peripheral tissues to the brain [28].
In addition to the well-recognized role of SOD1, increased OS could also be caused by the overproduction of Aβ, due to triplication of APP. This hypothesis is confirmed by a number of reports
demonstrating that both Aβ (1-40/42) are able to induce OS, as in the case of AD [8,29]. Indeed,
Butterfield and others [8,16,30,31] proposed that Aβ (1-42), in the form of oligomers, is able to insert
into the membranes initiating lipid peroxidation and downstream cascades [29]. Accordingly, the
levels of both Aβ (1-42) and Aβ (1-40) in plasma are higher in DS compared with non-DS controls
and deposition of senile plaques is observed in post-mortem brain from DS individuals [32,33], very
early in life. Further, Aβ has the ability to coordinate metal ions—Zn2+, Cu2+ and Fe2+—and the
alteration of metal homeostasis is known to regulate both production and defense against ROS and
is also involved in the regulation of neuronal activity in the synapses and other biological functions
in the brain. It is interesting to underlie that studies from Anandatheerthavarada et al. [34] for the
first time provided evidence that full length APP itself is able to damage mitochondria. Consistent
with their work, mice overexpressing wild type human APP show cognitive defects and neuronal
pathology similar to what observed in AD models, though these mice do not show significant Aβ
deposition in the hippocampus [35]. These findings support the notion that, in addition to effects
from APP-generated Aβ oligomers on mitochondria, trisomy of APP itself may promote
mitochondrial dysfunction in DS.
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BACH1, encoded on Hsa21, is a key element in the regulation of the antioxidant response in DS
[6]. BACH1 is a transcription repressor that acts as a key regulator of the expression of genes involved
in the cell stress response [36]. In DS, it is likely that upregulation of BACH1 protein levels could
block the induction of antioxidant genes, therefore promoting increased OS in the cell [6]. The
molecular aspects of BACH1 triplication will be discussed in the next section.
By mapping Hsa21, another candidate gene that is related to OS is the enzyme carbonyl
reductase (CBR). CBRs are NADPH-dependent cytosolic enzymes with broad substrate specificity for
many endogenous and xenobiotic carbonyl compounds. They catalyze the reduction of endogenous
prostaglandins, steroids, and other aliphatic aldehydes and ketones. Carbonyls are considered toxic
metabolic intermediates, that can be detoxified both through oxidation by aldehyde dehydrogenase
(ALDH) or by CBR-mediated reduction and/or alcohol dehydrogenase (ADH). Increased levels of
both these enzymes were detected in the brain of both DS and AD patients, likely in response to
elevated carbonyls production [37].
Published studies from our laboratories identified several oxidatively modified proteins in DS
brain, prior and after development of AD [5,38,39]. Among several targets, oxidation of proteins
could be particularly deleterious in aging and in age-related neurodegenerative diseases, due to a
gradual loss of efficiency of clearance systems for their removal [37]. The role of OS in the
development and progression of AD in the general population has been extensively discussed in
several review papers [8,40,41]. Among the proteins identified by redox proteomics to be oxidatively
modified, either by increased carbonylation or HNE modification, proteins involved in several
intracellular processes such as (i) neuronal trafficking; (ii) the proteostasis network; (iii) energy
metabolism; and (iv) mitochondrial function were found [6].
Reduced ATP levels, increased ROS, and altered mitochondrial permeability are characteristic
mitochondrial defects of degenerating neurons not only in DS but also in many neurodegenerative
disorders, including AD [8]. Overall, proteomics data demonstrate that oxidative damage is an early
event in DS, and the dysfunction of protein clearance systems contributes to increased neuronal
vulnerability to oxidative damage that accelerate neurodegenerative phenomena. As noted,
considering that several of the above-mentioned proteins have been already found to be oxidized in
AD brain, our results strongly support the notion that aberrant protein oxidation in DS may
contribute to age-dependent AD risk.
This view is also confirmed by a longitudinal study analyzing some redox markers in plasma
samples from DS subjects (1–57 years old) showing that changes in redox-related parameters are
strongly age-dependent [17]. Similarly, Pallardo and colleagues showed a significant increase in 8hydroxy-2-deoxyguanisine (8-OHdG) levels in DS patients up to 30 years old. Levels of antioxidants
including ascorbic acid and vitamin E also were evaluated, showing that plasma concentrations of
ascorbic acid are increased in young (<15 years) DS individuals, but not in older persons, while the
levels of vitamin E did not differ from control either in young or older DS individuals compared with
non-DS healthy individuals [17].
The picture that emerges from both brain and peripheral studies suggest that young DS
individuals are characterized by an early pro-oxidant state [27] that results in a variety of pathological
phenotypes. With age, adult DS persons accumulate oxidative damage associated with an increased
risk to develop Alzheimer-like dementia [20,22]. Understanding the complexity of factors regulating
redox homeostasis may help to identify potential therapeutic treatments able to prevent the
accumulation of oxidative damage. In this scenario, it is particularly interesting to discuss the role
played by BACH1/Nrf2 axis in DS.
2. BACH1/Nrf2 Signaling
Based on the considerations above, it is conceivable that OS occurs in DS pathogenesis and
progression due to a dysregulation of gene/protein expression associated with the trisomy. As noted
above, OS represents an imbalance between the production of ROS and the ability of a biological
system to detoxify the reactive toxic intermediates—the antioxidant response—or to repair the
resulting damage.

Antioxidants 2020, 9, 779

5 of 14

A prominent sensor involved in the antioxidant response is the Keap1-Nrf2-ARE (Kelch-like
ECH-Associating protein 1- nuclear factor erythroid related factor 2-antioxidant response element)
signaling complex. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) mediates
induction of multiple antioxidant enzymes through activation of ARE of DNA. Activation of Nrf2
results in cellular protection by increasing the expression of antioxidant enzymes such as NADPH
quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1), and multiple components of the
glutathione pathway. Promotion of this production of antioxidants is therefore a promising
mechanism to protect against neurodegeneration. Under normal OS conditions, Keap1, a cysteinerich protein that senses redox changes in the cell, binds to Nrf2 leading to retention of Nrf2 in the
cytosol and causing its proteasomal degradation [42,43]. Under OS, conformational changes in Keap1
lead to its dissociation from the Nrf2-Keap1 complex and to the translocation of free Nrf2 into the
nucleus, where it binds to ARE regions in the genome, to activate the expression of stress response
genes [44]. So far, there is no complete information on Nrf2/Keap1 genes, protein levels or activities
in DS. However, a recent study comparing gene expression profiles in DS and euploid astrocytes
found that Nrf-2-associated oxidative stress response genes were differentially regulated in DS [45].
In addition, a study from Swatton et al. in DS reported that mitogen-activated protein kinases
(MAPKs) are highly phosphorylate in DS and AD brains [46], and this result can be linked to the
mechanism whereby MAPKs phosphorylate Nrf2 enabling its dissociation from the Nrf2/Keap1
complex, but preventing its translocation into the nucleus.
Compared to Nrf2, ARE transcriptional repressors and their roles in DS, AD, and other
neurodegenerative disorders have been minimally investigated. Indeed, a novel hypothesis regards
the implication of BACH1 to compete with the Keap1-Nrf2-ARE signaling complex. BACH1 is a
member of the Cap “n.” Collar and basic region leucine zipper family (CNC-bZip) of transcription
factors is encoded on HSA21 and functions primarily as a transcriptional repressor. Human BACH1
is composed by 736 amino acids: (a) N-terminal region of BACH1 contains a BTB/POZ domain, which
functions as a protein interaction motif; (b) while the C-terminal bZip domain binds to DNA forming
heterodimers with small Maf proteins (i.e., MafK, MafF, and MafG) [47]. Once into the nucleus,
BACH1-Maf heterodimers are able to inhibit the transcription of many oxidative stress-response
genes. In addition, BACH1 contains six cysteine-proline (CP) motifs, four of which are located in a
heme-binding region near the C- terminus. Heme is able to inactivate BACH1 by interacting with two
of the CP motifs, leading to the exclusion of BACH1 from the nucleus [48]. Under pro-oxidant
condition, nuclear BACH1 binds heme, changes its conformation, dissociates from ARE and allows
transcription factors to bind and activate the expression of oxidative stress-responsive genes [49].
The export of BACH1 from the nucleus is also the result of its tyrosine phosphorylation,
activated by the antioxidant response, (BACH1 tyrosine 486) [50] and by cadmium, which induces a
cytoplasmic localization signal in the BACH1 C-terminus [51]. After its release in the cytoplasm,
BACH1 forms fiber-like structures on microtubules in the presence of intracellular hyaluronic acidbinding protein (IHABP), which regulates the subcellular localization of the former [51].
Many of the genes targeted by BACH1 are in common with the genes regulated by Nfr2 and
participate in redox regulation, including HO-1, that is crucial for cell survival upon detrimental
oxidative stress conditions. HO-1 expression is negatively regulated by BACH1 when heme levels
are reduced, though higher heme levels are able to inhibit BACH1-DNA interaction and also promote
BACH1 nuclear export and its subsequent degradation [52]. This event induces HO-1 expression,
which in turn degrades heme while releasing antioxidant molecules such as carbon monoxide (CO),
and biliverdin. Thus, the BACH1/HO-1 pathway is considered to act as a feedback loop that regulates
heme homeostasis during sustained oxidative stress.
Taken together, BACH1 is believed to displace Nrf2 from AREs [49] and to act primarily as a
transcriptional repressor for antioxidant genes, such as HO-1 [53] and NQO1 [54]. Specifically,
BACH1 competes with Nrf2 for binding to the AREs in oxidative stress-response genes. In response
to OS, Nrf2 dissociates from Keap1, translocates into the nucleus, and binds to AREs as a heterodimer
with Mafs, thereby activating oxidative stress-response genes as previously described, while BACH1
is displaced from AREs and exported out of the nucleus [49] (Figure 1). A recent study suggests that
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both the nuclear import of Nrf2 and the dissociation of BACH1-ARE are promoted by sirtuin-6 (Sirt
6) [55]. Research from Dhakshinamoorthy et al. demonstrated that positive and negative regulation
of ARE-mediated gene expression depend on the critical balance between Nrf2 and BACH1 in the
nucleus. This was clearly evident from the observation that BACH1 repression of ARE-mediated gene
expression was relieved by co-expression of Nrf2 with BACH1, and BACH1 failed to repress the ARE
in cells overexpressing Nrf2. However, BACH1 repressed the ARE activation in cells expressing
moderate levels of Nrf2 [54].

Figure 1. BACH1/Nrf2 signaling regulates antioxidant response. Under normal conditions (left),
Keap1/Nrf2 retains Nrf2 in the cytoplasm. Exposure of cells to oxidative insult leads to the release of
Nrf2 from Keap1/Nrf2. Nrf2 then translocates to the nucleus and binds to MAREs as a heterodimer
with small Mafs, thereby activating oxidative stress-response genes (e.g., HO-1 and NQO1), while
Bach1 is displaced from MAREs and exported out of the nucleus. In trisomic cells (DS) (right),
triplication of BACH1 competes with Nrf2 thus resulting in reduced binding of Nrf2 to MAREs. This
event may explain the increased oxidative stress levels of DS individuals, that is likely the result of
compromised induction of antioxidant response.

In light on these findings, focusing on DS individuals, the triplication of genes (e.g., BACH1)
encoded on HSA21 is directly involved in the appearance of harmful conditions such as increased
OS, which we hypothesize over time contributes to the early development of AD pathology in DS
individuals. The presence of BACH1 on HSA21 opens the possibility of seeking new therapies
capable of controlling the possible imbalance between Nrf2 and BACH1 in the nucleus.
3. Involvement of BACH1 in AD and DS
The evaluation of BACH1 functions in the brain and particularly in neurodegenerative disorders
characterized by a failure of antioxidant responses, represents a novel aspect of DS research. Indeed,
only a limited number of studies addressed this topic to date.
Studies performed in BACH1 knock-out mice (BACH1−/−) showed significantly higher HO-1
mRNA expression levels with respect to control animals in all brain regions studied [56]. Moreover,
higher induction of HO-1 was observed around damaged tissues in BACH1−/− mice [56]. Similar
results were collected with regard to spinal cord where HO-1 protein levels were found significantly
higher in BACH1−/− than WT mice either before or after injury [57]. Furthermore, neuronal loss and
apoptotic cell death in the injured spinal cord was significantly reduced in BACH1−/−mice [57]. Thus,
as described above, these results confirm that BACH1 plays an important role in regulating HO-1
expression levels in the central nervous system.
The first evidence about a possible involvement of BACH1 in brain disorders came in 2003 when
Shim et al. evaluated levels of BACH1 protein levels in a small cohort of post-mortem frontal cortex
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samples collected from DS, AD, and related control individuals to test the hypothesis that DSphenotype may be due to the overexpression of genes encoded on chromosome 21 [58]. Despite the
prevalent hypothesis of a gene-dosage effect in DS, these authors found that BACH1 protein levels
were significantly reduced in DS samples, suggesting that DS features cannot be simply explained by
the overexpression of triplicated genes [58]. However, these findings were revised by the same group
published in a subsequent study [59]. In the afore-mentioned work, fetal cortical specimens from DS
fetuses and controls (females) from the 18-19th week of gestation were used to evaluate BACH1
protein levels and levels of one of the targets of BACH1 activity, i.e., HO-1, among the others [59].
BACH1 was significantly overexpressed in fetal DS as compared to controls [59], while the levels of
HO-1 were found comparable between the two groups [59]. In light of these results these researchers
concluded that increased BACH1 did not lead to decreased HO-1, which would have explained
oxidative stress observed in fetal DS [59].
However, we suggest that the above conclusion could be criticized. Considering that HO-1 is
inducible, with lower intracellular levels under physiological conditions, HO-1 levels are
dynamically responsive to a variety of oxidative and inflammatory stimuli such as heme, Aβ, H2O2,
heavy metals, UV light, hyperoxia, prostaglandins, nitric oxide (NO), peroxynitrite,
lipopolysaccharide, oxidized lipid products and various growth factors [60–62]. Further, in the adult
brain, HO-1 expression in basal conditions is restricted to sparse clusters of neurons and glia [60].
While in the unstressed rodent brain, low-level of HO-1 is observed in scattered neurons of the
cerebral cortex, hippocampal dentate gyrus, thalamus, hypothalamus, and cerebellum [63–67].
Hence, reduced HO1 levels in DS frontal cortex might not be expected. The reason could simply be
that increased BACH1 levels would prevent HO1 overexpression, which remains at similar levels to
those observed in the control group. If considered in this way, no changes observed for HO-1 levels
would lead to increased oxidative stress levels in DS brain, since HO-1 is among the first proteins
induced to elicit an antioxidant response under conditions of increased oxidative stress levels [68–
70].
This hypothesis was further strengthened by proposing a role for BACH1 overexpression as one
of the causes driving the development of neurodegeneration in DS [6]. Indeed, the expression levels
and the ubiquitinylation of BACH1 were evaluated in post-mortem frontal cortical samples isolated
from postmortem DS persons before and after (DSAD) the development of AD neuropathology,
compared to age-matched controls [6]. Moreover, the incident effects of BACH1 on HO-1 and on its
physiological partner biliverdin reductase-A (BVR-A)—both involved in the production of the
antioxidant molecule bilirubin [60,61]—as well as the levels of NQO1, were determined. Results from
this study highlighted that BACH1 protein levels are significantly elevated in DS subjects, either
before or after the development of AD [6]. Furthermore, the evaluation of BACH1 post-translational
modifications revealed that BACH1 mono-ubiquitinylation levels were reduced only in DS, while
increased levels of BACH1 poly-ubiquitinylation were observed only in DSAD subjects [6].
In parallel, it was observed that neither HO-1 or NQO1 protein levels (both regulated by BACH1,
[53,54]) were different between DS and age-matched controls, while they were significantly
increased in brains from the DSAD group [6]. Observations collected from DS individuals are in
agreement with those previously reported by the group of Lubec and co-workers [59]. Moreover,
further studies contributed to extending the knowledge about the regulation of BACH1 in DS.
Indeed, by taking into consideration that mono-ubiquitinylation is involved in modulating protein
function, compartmentalization, and interactions, while polyubiquitinylation is a signal for protein
degradation [71,72], collectively, the results suggest that more than the expression levels, the
regulation of BACH1 activity/degradation plays a role in DS and contributes to the explanation of
observed changes with regard to HO-1 [6]. Increased BACH1 protein levels along with reduced
BACH1 mono-ubiquitinylation would be responsible for the lack of HO-1 or NQO1 increase observed
in DS, while increased BACH1 poly-ubiquitinylation (degradation) would drive the observed
increase of HO1 and NQO1 protein levels in DSAD persons [6]. Increased BACH1 polyubiquitinylation could result from increased oxidative stress levels in DSAD individuals [6]. Similar
analyses performed in a mouse model of DS, i.e., Ts65Dn mice, at different ages further suggest that
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BACH1 overexpression results from the triplication of chromosome 21, although the mechanisms
associated with BACH1 regulation appear different between mice and humans [6]. Indeed, the
overexpression of BACH1 was not associated with differences in the ubiquitinylation profile between
Ts65Dn and control mice [6]. Increased BACH1 levels in Ts65Dn mice tend to maintain HO-1
expression levels comparable to those of euploid animals [6].
The pivotal role for BACH1 in the regulation of antioxidant response in DS is further highlighted
by data collected with regard to BVR-A. As indicated above, BVR-A is normally co-expressed with
HO-1 to promote the degradation of pro-oxidant heme into the antioxidant molecule bilirubin [61,73].
Notwithstanding that BVR-A possesses pleiotropic functions through which this enzyme regulates
intracellular signaling [73]. Among these functions, Maines’ group identified BVR-A as a hemebinding and heme transport protein, and suggested its role in the modulation of the expression of
heme-regulated genes [74]. In particular, these researchers proposed that transport of heme to the
nucleus by BVR-A would enable its delivery to the transcriptional repressor BACH1, which, on
binding heme dissociates from the DNA, and is replaced by the Nrf2 transcription factor [74]. Indeed,
cells lacking BVR-A were characterized by reduced HO-1 expression in response to heme [74].
Moreover, increased BVR-A levels were observed in both DS and DSAD individuals with respect to
age-matched controls [6]. However, they were not associated with increased HO1, particularly in DS,
further suggesting that over-expression of BACH1 precludes HO-1 upregulation mediated by
physiological activators, including BVR-A.
Studies about the possible involvement of BACH1 in AD neuropathology mostly rely with in
vitro analyses. The only report aimed to evaluated levels of BACH1 in AD brain shows no changes
with respect to control subjects [58]. This gap in knowledge about functions of BACH1 in AD needs
to be fulfilled in future studies, particularly in light of the role for HO1 and reduced antioxidant
response in the onset and progression of AD pathology [60,61,75]. While HO-1 and NQO1 protein
proteins levels are elevated in AD brain (reviewed in [61,76]), reduced Nrf2 activity was reported in
a number of studies performed on human and animal samples. Indeed, reduced Nrf2 nuclear
expression in hippocampal samples from AD subjects were observed [77]. Similarly, a failure of Nrf2mediated processes in AD mouse models was reported [78–81]. Together, these observations spur
the necessity for deeper investigations into a possible role for BACH1 in AD.
A previous study showed that BACH1 also targets the gene for microtubule-associated protein
tau (also known as MAPT)—known to drive AD progression [82]—by repressing its expression [83].
In this context, Koglsberger et al. reported that BACH1 expression contributes to molecular gender
differences observed in tauopathies and AD and provides a new target for intervention strategies to
modulate MAPT expression [84]. Since gender differences may influence the risk for brain disorders
and the severity of their phenotypic manifestations, the role for BACH1 appears of great interest.
Indeed, there is evidence of a gender difference in the phenotypic expression of AD in DS. Female
middle-aged DS individuals have an earlier onset and a more severe form of AD that correlates with
higher neocortical neurofibrillary tangles (NFT) rather than senile plaques (SP) density (2).
Among the in vitro studies that assessed a role for BACH1 in neuronal injury, Piras et al.
evaluated the effects of increased oxidative stress levels, mimicked by H2O2, in differentiated SHSY5Y cells [85]. A striking finding of this work is represented by the fact that in differentiated cells
BACH1 is not displaced from the HO-1 promoter and Nrf2 is not allowed to bind, while maintaining
its ability to sense H2O2 moving into the nucleus [85]. In addition, BACH1 and Nrf2 mRNA levels
were not modified by increased oxidative stress levels, further corroborating the hypothesis that the
main regulation of both BACH1 and Nrf2 occurs at the post-transcriptional level [85]. These results
agree with findings from our group with regard to DS (cited above) and reinforce the hypothesis that
the sole evaluation of protein and/or transcripts levels are not sufficient to unravel the molecular
mechanisms regulated by BACH1 (Table 2).
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Table 2. Summary of BACH-1 alterations observed in Down syndrome and Alzheimer disease.
Pathology

BACH1 Changes
↑ BACH1 protein levels in fetal cortical
specimens of human DS

Down
Syndrome (DS)

Alzheimer
Disease (AD)

↑ BACH1 protein levels in human DS subjects,
either before or after the development of AD
Changes in post-translational modifications of
BACH-1:
↓ mono-ubiquitination of BACH1 in young DS
human brain
↑ poly-ubiquitinylation of BACH1 only in DSAD
subjects
↑ BACH1 protein levels in brain of Ts65Dn mice.
No changes were observed in BACH1
ubiquitination in Ts65Dn mice compared to
euploid mice.
NO changes were observed in BACH1 protein
levels in AD brain.
↑ BACH1 protein levels in AD Brain using an
immunohistochemistry approach.

References
Ferrando-Miguel R.J. Neural Transm Suppl,
2003(67): p. 193-205 Tili, E., et al., Ann Diagn
Pathol, 2018. 34: p. 103-109.
Di Domenico, F., et al., J.Alzheimers Dis, 2015.
44(4): p. 1107–20.

Di Domenico, F., et al., J.Alzheimers Dis, 2015.
44(4): p. 1107–20.

Di Domenico, F., et al., J.Alzheimers Dis, 2015.
44(4): p. 1107–20.
Shim, K.S., R. Ferrando-Miguel, and G. Lubec, J
Neural Transm Suppl, 2003(67): p. 39–49.
Tili, E., et al., Ann Diagn Pathol, 2018. 34: p. 103–
109.

Finally, a role for specific micro RNAs (miRNAs) in regulating BACH1 expression was
identified. miRNAs are key regulatory molecules, given their ability to disrupt expression of target
mRNAs [86]. With the attempt to better clarify potential regulators of BACH1 in DS, Tili et al.
evaluated the expression levels of miR155, which is one of the miRNA encoded on chromosome 21
that also targets the BACH1 gene [87]. These scientists found that miR-155 is overexpressed only in
DS brain, but not in control samples or even in AD samples took as reference [87]. Furthermore, these
researchers found BACH 1 protein was strongly expressed in the DS fetal brain tissues, but not in
adult DS with dementia with respect to controls [87]. Reduced BACH1 levels in DS with dementia
with respect to AD samples were also observed [87]. miR-155/BACH1 levels strongly correlated with
the disease process in DS [87]. The results from Tili et al. are apparently in contrast to the
overexpression of BACH1 found by Di Domenico et al. [6]. However, there are two key points that
deserve attention because they represent differences between the two studies. The number of DS
samples (samples were collected from 3 DS donors in Tili et al. [87] vs. 8 samples in Di Domenico et
al. [6]), and the age of the donors was different as well (34 to 42 in Tili et al. [87] vs. 59 in Di Domenico
et al. [6]). Furthermore, in Tili et al. AD samples were not matched for age with Control or DS, were
used [87]. Hence, in our opinion, the conclusions about the strong association between miR155/BACH1 and the development of dementia in DS require more extensive investigation.
Another miRNA identified through a bioinformatic analysis as a potential regulator of BACH1
is miR-98-5p [88]. miR-98-5p is a stress-related miRNA that plays an important role in regulating cell
survival, apoptosis, and oxidative stress in multiple cell types and diseases [88]. Sun et al. reported
that miR-98-5p alleviates neuronal injury induced by oxygen-glucose deprivation/reoxygenation, by
also reducing reactive oxygen species levels [88]. Indeed, overexpression of miR-98-5p significantly
suppressed the expression of BACH1 at the mRNA and protein levels, while inhibition of this micro
RNA promoted the expression of BACH1 [88]. miR-98-5p overexpression also significantly increased
the nuclear translocation of Nrf2 and promoted the activity of ARE [88]. As a consequence, the
transcription of NQO1 and HO-1 also were significantly upregulated [88]. The role of miR-98-5p was
confirmed by showing that BACH1 overexpression reversed the neuroprotective effects mediated by
miR-98-5p overexpression [88]. These findings suggest a neuroprotective role for miR-98-5p by
affecting the oxidative stress response through BACH1 suppression.
4. Concluding Remarks
Collected evidence suggests that young DS individuals are characterized by an early pro-oxidant
state that contributes to a variety of pathological phenotypes. Among the genetic elements involved

Antioxidants 2020, 9, 779

10 of 14

in the regulation of redox homeostasis, triplication of SOD1 and BACH1, are considered to play a
major role. Since SOD1 is directly responsible for production of hydrogen peroxide, triplication of
BACH1 has wider effects because of its role in the BACH1/Nrf2 axis-induced antioxidant response.
Considering that with age adult DS individuals accumulate oxidative damage in brain associated
with an increased risk to develop Alzheimer-like dementia, modulation of the BACH1/Nrf2 axis in
DS may represent a promising therapeutic strategy. Further studies are needed to dissect the
complexity of targets that are controlled by BACH1/Nrf2 signaling and the potential mechanisms
that are relevant to aging and neurodegeneration not only in DS but also in AD and, potentially, in
other neurodegenerative disorders.
Funding: This research was funded in part by a NIH grant to D.A.B. [AG-055596-01A1], and the APC was funded
by the same grant.
Conflicts of Interest: The authors declare no conflict of interest.
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